7,80 $ Pipeline. Advanced medicines that demonstrate both strong clinical performance and benefits to patients.

ABBV-101 is a small molecule BTK degrader that is being investigated to treat B-cell malignancies.

5 июн. 2024 г. · We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are ...

28 мая 2024 г. · Today, our expansive oncology portfolio comprises of approved and investigational treatments for a wide range of blood and solid tumors. We are ...

5 февр. 2024 г. · AbbVie's oncology pipeline could do with a boost: its late-stage highlights consist largely of new uses for approved products, as well as the ...

5 июн. 2024 г. · Over the course of 52 weeks of treatment, Zepbound helps patients lose on average 24% of their mass, whereas Wegovy has been shown in clinical ...

ABBV-303 c-Met TriNKET is designed to work with a wide range of other I/O drugs, as well as with other traditional treatment approaches in oncology, such as ...

14 окт. 2024 г. · AbbVie is seeking accelerated approval for its cancer drug Teliso-V following positive data from a Phase 2 trial.

3 июн. 2024 г. · Abbvie presented positive Phase I and II trial data for three ADC therapies, Teliso-V, ABBV-400 and ABBV-706, in solid tumour patients.

AbbVie's oncology pipeline includes multiple new molecules in clinical trials being studied in more than 15 different cancers and tumor types. For more ...